Abstract
The treatment strategy for metastatic renal cell carcinoma (mRCC) has evolved with the emergence of anti-angiogenic drugs, in particular tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor receptor (VEGFR) and immune checkpoint inhibitors (ICIs). Both treatment options improved patient outcomes and altered the natural history of mRCC. Clinical studies have focused on evaluating combination regimens containing ICI and VEGFR-targeted TKIs. The combination of axitinib with pembrolizumab (KEYNOTE-426) showed better results compared to sunitinib in patients with mRCC who had not previously received systemic therapy. In this article, we discuss the rationale for the combination of ICI and TKI based on preclinical data, as well as the clinical results obtained with the combination of axitinib with pembrolizumab in first-line patients in clinical trials.
Highlights
Combination of pembrolizumab and axitinib: a new gold standard in the first-line therapy for metastatic clear-cell renal-cell carcinoma? R
Clinical studies have focused on evaluating combination regimens containing immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitors (TKIs)
The combination of axitinib with pembrolizumab (KEYNOTE-426) showed better results compared to sunitinib in patients with metastatic renal cell carcinoma (mRCC) who had not previously received systemic therapy
Summary
Clinical studies have focused on evaluating combination regimens containing ICI and VEGFR-targeted TKIs. The combination of axitinib with pembrolizumab (KEYNOTE-426) showed better results compared to sunitinib in patients with mRCC who had not previously received systemic therapy. Что ингибиторы иммунной контрольной точки (ICI), нацеленные на поверхностные рецепторы опухолевых или иммунных клеток, запускающие иммунную толерантность, эффективны у пациентов, как не получа вших, так и ранее получавших лечение при мПКР [7]. В настоящей статье мы обсуждаем обоснование комбинации ICI и TKI на основе доклинических данных, а также клинические результаты, полученные при использовании комбинации акситиниба с пембролизумабом у пациентов в 1-й линии терапии в клинических исследованиях при мПКР.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
